blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3578204

EP3578204 - CONJUGATE OF BIOACTIVE MATERIAL HAVING ENHANCED SUSTAINABILITY AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  08.11.2019
Database last updated on 24.08.2024
FormerThe international publication has been made
Status updated on  11.08.2018
Most recent event   Tooltip19.02.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Hanmi Pharm. Co., Ltd.
214 Muha-ro
Paltan-myeon
Hwaseong-si, Gyeonggi-do 18536 / KR
[2019/50]
Inventor(s)01 / PARK, Young Jin
550 Dongtangiheung-ro
Hwaseong-si Gyeonggi-do 18469 / KR
02 / LEE, Jong-Soo
550 Dongtangiheung-ro
Hwaseong-si Gyeonggi-do 18469 / KR
03 / CHOI, In Young
550 Dongtangiheung-ro
Hwaseong-si Gyeonggi-do 18469 / KR
 [2019/50]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2019/50]Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date18748653.502.02.2018
[2019/50]
WO2018KR01458
Priority number, dateKR2017001566303.02.2017         Original published format: KR 20170015663
KR2017012718729.09.2017         Original published format: KR 20170127187
[2019/50]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018143729
Date:09.08.2018
Language:KO
[2018/32]
Type: A1 Application with search report 
No.:EP3578204
Date:11.12.2019
Language:EN
[2019/50]
Search report(s)International search report - published on:KR09.08.2018
(Supplementary) European search report - dispatched on:EP04.12.2020
ClassificationIPC:A61K47/68, A61K47/60, A61K38/28, A61P1/18, A61P3/10, A61P5/48, A61P5/50
[2021/01]
CPC:
A61K38/28 (EP,KR,US); A61K47/60 (EP,KR,US); A61K47/68 (EP);
A61K47/6801 (US); A61K47/6803 (KR); A61K47/6811 (KR);
A61K47/6889 (KR); A61P1/18 (EP); A61P3/10 (EP);
A61P5/48 (EP); A61P5/50 (EP) (-)
Former IPC [2019/50]A61K47/60, A61K47/68, A61K38/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/50]
TitleGerman:KONJUGAT AUS BIOAKTIVEM MATERIAL MIT ERHÖHTER BESTÄNDIGKEIT UND VERWENDUNG DAVON[2019/50]
English:CONJUGATE OF BIOACTIVE MATERIAL HAVING ENHANCED SUSTAINABILITY AND USE THEREOF[2019/50]
French:CONJUGUÉ DE SUBSTANCE BIOACTIVE AYANT UNE DURABILITÉ AMÉLIORÉE ET SON UTILISATION[2019/50]
Entry into regional phase14.08.2019Translation filed 
14.08.2019National basic fee paid 
14.08.2019Search fee paid 
14.08.2019Designation fee(s) paid 
14.08.2019Examination fee paid 
Examination procedure14.08.2019Examination requested  [2019/50]
29.06.2021Amendment by applicant (claims and/or description)
Fees paidRenewal fee
19.02.2020Renewal fee patent year 03
19.02.2021Renewal fee patent year 04
09.02.2022Renewal fee patent year 05
21.02.2023Renewal fee patent year 06
19.02.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2008082274  (HANMI PHARMACEUTICAL CO LTD [KR], et al) [X] 1-6,11-15 * examples 1-12; paragraph 115; claim 21, 33. *;
 [X]KR20110134209  (HANMI HOLDINGS CO LTD [KR]) [X] 1-15 * embodiments 10-12, paragraph 65, claim 10, 16 *;
 [X]CA2913886  (HANMI PHARM IND CO LTD [KR]) [X] 1-6,11-14 * example 1 *;
 [X]CA2950266  (HANMI PHARM IND CO LTD [KR]) [X] 1-15 * examples 8 -11, claims 23-26, page 17-18 *;
 [XD]WO2015183054  (HANMI PHARM IND CO LTD [KR]) [XD] 1-15 * example 8, paragraph 64, claim 1, 12, 20 *;
 [X]WO2015186988  (HANMI PHARM IND CO LTD [KR]) [X] 1-6,11-15* example 3, paragraph 118 and 149, page 19 *;
 [X]EP2963056  (HANMI PHARM IND CO LTD [KR]) [X] 1-15 * examples 8-11, paragraph 74, claim 17 and 23 *;
 [X]EP3098235  (HANMI PHARM IND CO LTD [KR]) [X] 1-15 * examples 8-11; paragraph 99 and 128, claim 30 and 32 *;
 [X]CA2991107  (HANMI PHARM IND CO LTD [KR]) [X] 1-6,11-15 * example 6; paragraph 420; claim 28, 32 *;
 [AP]WO2017052321  (HANMI PHARM IND CO LTD [KR]) [AP] 1-15 * whole document, in particular paragraph [0208] *;
 [XP]WO2017052329  (HANMI PHARM IND CO LTD [KR]) [XP] 1-14 * examples 1, 2, 3+7, 4, 5, 6, 11; paragraph 125, claim 9 *;
 [XP]WO2018004283  (HANMI PHARM IND CO LTD [KR]) [XP] 1-6,11-15 * example 6; paragraph 205 and 208; claim 31 and 51 *;
 [E]WO2018105988  (HANMI PHARM IND CO LTD [KR]) [E] 1-14 * preparation example 1, section (1)-(3); paragraph 93 *;
 [E]EP3341025  (HANMI PHARM IND CO LTD [KR]) [E] 1-14;
 EP3354664  [ ] (HANMI PHARM IND CO LTD [KR]);
 [E]WO2018174668  (HANMI PHARM IND CO LTD [KR]) [E] 1-15 * the whole document *;
 [E]WO2019066603  (HANMI PHARM IND CO LTD [KR]) [E] 1-15 * the whole document *;
 [E]EP3479841  (HANMI PHARM IND CO LTD [KR]) [E] 1-6,11-15;
 [E]EP3549950  (HANMI PHARM IND CO LTD [KR]) [E] 1-14;
 EP3604328  [ ] (HANMI PHARM IND CO LTD [KR]);
 EP3689914  [ ] (HANMI PHARM IND CO LTD [KR])
International search[X]KR20080064750  (HANMI PHARM IND CO LTD [KR]) [X] 1-6, 12-18* See paragraphs [0011], [0053], [00601; and claims 1-33. *;
 [X]KR20110134209  (HANMI HOLDINGS CO LTD [KR]) [X] 1-8, 12-18 * See paragraphs [0031], [0065]; and claims 1-20. *;
 [X]KR20150087130  (HANMI PHARM IND CO LTD [KR]) [X] 1-18 * See paragraph [0080]; example 8; and claims 1-32. *;
 [X]KR20150138101  (HANMI PHARM IND CO LTD [KR]) [X] 1-18 * See paragraphs [0034]. [0046]. [0089]; example 8; and claims 1-18. *;
 [X]KR20160001391  (HANMI PHARM IND CO LTD [KR]) [X] 1-14, 17-18 * See claims 1-17. *;
 [X]KR20160007295  (HANMI PHARM IND CO LTD [KR]) [X] 1-14, 17-18 * See paragraphs [0055], [0056], [0084]; and claims 1-20. *;
 [X]KR20170003466  (HANMI PHARM IND CO LTD [KR]) [X] 1-7, 12-18 * See paragraphs [0167], [0420]; examples 5, 6; and claims 1-45. *
by applicantWO9632478
 WO9734631
 WO0104329
 KR20010009171
 KR20090008151
 WO2009011544
 WO2012169798
 KR20120137271
 KR20120139579
 WO2012173422
 KR20140106452
 WO2015108398
 KR20150087130
 WO2015183054
 WO2016043533
 WO2016108586
 WO2017003191
 KR20170026284
 WO2017039267
 WO2017116205
 WO2017116204
    - AUTHIER F et al., Biochem J., (19980601), vol. 332, pages 421 - 30
    - DUCKWORTH WC et al., Endocr Rev., (19981000), vol. 19, no. 5, pages 608 - 24
    - VALERA MORA ME et al., J Am Coll Nutr, (20031200), vol. 22, no. 6, pages 487 - 93
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.